ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "spondyloarthritis"

  • Abstract Number: 1740 • ACR Convergence 2022

    Chronic Inflammation in Patients with Rheumatoid Arthritis or Spondyloarthritis Alters Regulatory T Cells Identity

    Tessnime Abaab1, Lyna Mebrek1, Marie-Christophe Boissier2, Luca Semerano3, Jerome Biton1 and Natacha Bessis1, 1INSERM UMR 1125, Sorbonne Paris Nord University, Bobigny, France, 2INSERM UMR 1125, Sorbonne Paris Nord University,Rheumatology Dpt, APHP, GHUPSSD, Avicenne Hosp, Bobigny, France, 3Hopital Avicenne - AP-HP, Sorbonne Paris Nord University, INSERM UMR1125, Bobigny Cedex, France

    Background/Purpose: Rheumatoid arthritis (RA) and spondyloarthritis (SpA) are inflammatory autoimmune diseases associated with impaired regulatory T cell (Tregs) function. Tregs identity varies according to their…
  • Abstract Number: 2259 • ACR Convergence 2022

    Complete Resolution of Inflammation on MRI Is Associated with a Better Clinical Response over Time in Patients with Early Axial Spondyloarthritis

    valeria Rios-Rodriguez1, Murat Torgutalp2, Christian Althoff3, Hildrun Haibel2, Kay-Geert Hermann2, Fabian Proft4, Mikhail Protopopov5, Judith Rademacher5, Joachim Sieper2 and Denis Poddubnyy4, 1Charité-Universitätsmedizin Berlin, Berlin, Germany, 2Charité - Universitätsmedizin, Berlin, Berlin, Germany, 3Helios Klinikum Emil von Behring, Berlin, Germany, 4Department of Gastroenterology, Infectious Diseases and Rheumatology, Charité – Universitätsmedizin Berlin, Berlin, Germany, 5Charité Universitätsmedizin Berlin, Berlin, Germany

    Background/Purpose: Magnetic resonance imaging (MRI) of the spine and sacroiliac joints (SIJ) are important tools for the diagnosis of axial SpA and the presence of…
  • Abstract Number: 0397 • ACR Convergence 2022

    Aberrant Global DNA Methylation in Peripheral Blood Cell Subpopulations of Patients with Axial Spondyloarthritis

    ERIC TOUSSIROT1, Sebastien Pasquereau2, Charline Vauchy3, Daniel Wendling4, Jean Charles Balblanc5, caroline Laheurte6, Marc Puyraveau7 and Georges Herbein2, 1CHU de Besançon, Besançon, France, 2EA EPILAB, Besancon, Besançon, France, 3INSERM CIC-1431, Besancon, Besançon, France, 4CHU, University Teaching Hospital, Besançon, France, 5Rhumatologie, Hopital Nord Franche Comté, Trevenans, France, 6EFS Bourgogne Franche Comté, Biomonotoring Plateform, Besançon, France, 7INSERM CIC-1431 CHU, Besançon, France

    Background/Purpose: Axial spondyloarthritis (axSpA) corresponds to a group of chronic inflammatory diseases mainly affecting the axial skeleton. TNFa and IL-17A have been identified as key…
  • Abstract Number: 0425 • ACR Convergence 2022

    Upadacitinib Pharmacokinetics and Exposure-Response Relationships for Efficacy and Safety in Axial Spondyloarthritis – Analyses of the Phase 3 Studies (SELECT-AXIS 1 and 2)

    Sumit Bhatnagar1, Doerthe Eckert2, Sven Stodtmann2, In-Ho Song3, Peter Wung3, Wei Liu3 and Mohamed-Eslam Mohamed3, 1AbbVie, Highland Park, IL, 2AbbVie, Ludwigshafen, Germany, 3AbbVie, Inc., North Chicago, IL

    Background/Purpose: The efficacy and safety profile of 15 mg once-daily (QD) upadacitinib (UPA), an oral, reversible, JAK inhibitor has been established in axial spondyloarthritis (axSpA),…
  • Abstract Number: 1009 • ACR Convergence 2022

    Efficacy and Improvement in Patient-Reported Outcomes at Weeks 16 and 52 in Ixekizumab Treated Biological Naïve Patients with Radiographic Axial Spondyloarthritis Achieving Clinically Important Pain at Night Reduction at Week 16: Results from COAST-V Trial

    Sofia Ramiro1, Cédric Lukas2, Michael Nissen3, Yves Schymura4, Khai Jing Ng4, Andrew Bradley4, Gabriel Doridot4, Soyi Liu-Leage5, Antoni Chan6 and James Cheng-Chung WEI7, 1Leiden University Medical Center, Leiden, Netherlands, 2University Hospital Centre Montpellier, University of Montpellier, Montpellier, France, 3Hopitaux Universitaires de Genève, Geneva, Switzerland, 4Eli Lilly and Company, Indianapolis, IN, 5Eli Lilly, Neuilly sur Seine, France, 6Royal Berkshire NHS Foundation Trust, Reading, United Kingdom, 7Chung Shan Medical University Hospital, Taichung, Taiwan

    Background/Purpose: Ixekizumab (IXE), a monoclonal antibody that selectively targets interleukin IL-17A, has shown efficacy in patients with radiographic axial spondyloarthritis (r-axSpA). Spinal pain, in particular…
  • Abstract Number: 1154 • ACR Convergence 2022

    Axial Spondyloarthritis: Profiling of MiRNAs in Peripheral Blood Mononuclear Cells

    Aneta Pekčcová1, Kristýna Bubová2, Monika Gregova3, Šárka Forejtová2, Jana Hořínková2, Markéta Hušáková2, Michal Tomcik4, Jindřiška Gatterová2, Jiří Vencovský5, Karel Pavelka6, Ladislav Šenolt5 and Jiří Baloun2, 1Institue of Rheumatology, Prague, Prague, Czech Republic, 2Institue of Rheumatology, Prague, Czech Republic, 3Institue of Rheumatology, Prague, 4Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic, 5Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, 6Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, Praha, Czech Republic

    Background/Purpose: microRNAs (miRNAs) are small non-coding RNAs, which are essential for correct gene expression. The dysregulation in miRNA expression is accompanied by various diseases and…
  • Abstract Number: 1491 • ACR Convergence 2022

    Clinically Relevant Differences in the Mobility of Patients with Axial Spondyloarthritis Related to Daytime of Performance

    David Kiefer1, Juergen Braun1, Lucia Schneider1, Niklas Kolle1, Uta Kiltz1, Ioana Andreica2, Philipp Sewerin1, Bjoern Buehring3, susanne herbold1 and Xenofon Baraliakos4, 1Rheumazentrum Ruhrgebiet, Herne, Germany, 2Rheumazentrum Ruhrgebiet, Ruhr-Universität-Bochum, Herne, Germany, 3Bergisches Rheuma-Zentrum, Velbert, Germany, 4Rheumazentrum Ruhrgebiet Herne, Herne, Germany

    Background/Purpose: Patients with axial spondyloarthritis (axSpA) often experience impairments of spinal mobility and physical function due to inflammation and structural damage. Back pain and morning…
  • Abstract Number: 1748 • ACR Convergence 2022

    Deep Immune Profiling of Cytotoxic T Cells (CTL) from Patients with Ankylosing Spondylitis Revealed a Subset of CTL Co-Expressing PD-1 and TIGIT That Resists Immune Exhaustion

    Michael Tang1, Addison Pacheco2, Zoya Qaiyum3, Melissa Lim1 and Robert Inman1, 1University Health Network, Toronto, ON, Canada, 2University of Toronto, Toronto, ON, Canada, 3Krembil Research Institute, Toronto, ON, Canada

    Background/Purpose: Unresolved, chronic inflammation is a key feature of Ankylosing Spondylitis (AS) yet the immunological events perpetuating remain unclear. The strongest genetic association with AS…
  • Abstract Number: PP07 • ACR Convergence 2022

    Remissions and Vigilance

    Michael Scepaniak, Cockeysville, MD

    Background/Purpose: I've been diagnosed with spondyloarthritis (SpA) for a little more than 7 1/2 years. That diagnosis was preceded by roughly 9 months of significant…
  • Abstract Number: 0398 • ACR Convergence 2022

    Comparison of Spondyloarthritis, Rheumatoid Arthritis and Knee Osteoarthritis Occurring in the Setting of HIV Infection

    Benjamin Naovarat1, John Reveille1, Mark Hwang2, Francis Williams3 and Gloria Salazar4, 1University of Texas McGovern Medical School, Houston, TX, 2McGovern Medical School at the University of Texas Health Science Center at Houston, Houston, TX, 3Specialists for Health/Wellmed, Shavano Park, TX, 4University of Texas Medical School at Houston/McGovern Medical School, Houston, TX

    Background/Purpose: Early in the HIV epidemic, autoimmune diseases such as lupus and rheumatoid arthritis (RA) were uncommonly encountered. With the advent of combined antiretroviral therapy…
  • Abstract Number: 0427 • ACR Convergence 2022

    Recapture Rates with Ixekizumab After Withdrawal of Therapy in Patients with Axial Spondyloarthritis: Results at Week 104 from a Randomized Placebo-controlled Withdrawal Study

    Robert Landewé1, Denis Poddubnyy2, Proton Rahman3, Rebecca Bolce4, Soyi Liu-Leage5, Jeffrey Lisse6, So Young Park7 and Lianne Gensler8, 1Amsterdam University Medical Center, Meerssen, Netherlands, 2Department of Gastroenterology, Infectious Diseases and Rheumatology, Charité – Universitätsmedizin Berlin, Berlin, Germany, 3Memorial University, St. John's, NL, Canada, 4Eli Lilly and Company, Cincinnati, OH, 5Eli Lilly, Neuilly sur Seine, France, 6Eli Lilly and Company, Tucson, AZ, 7Eli Lilly and Company, Indianapolis, IN, 8Department of Medicine, Division of Rheumatology, University of California San Francisco, San Francisco, CA

    Background/Purpose: Here, we describe the final results of the first study of patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis re-randomized to either placebo (ixekizumab…
  • Abstract Number: 1010 • ACR Convergence 2022

    Comparison of Established and New, Preliminarily Proposed ASAS Cut-Offs for Inflammatory MRI Lesions in the Sacroiliac Joints of Axial Spondyloarthritis Patients and Implications for Recruitment in Clinical Studies

    Xenofon Baraliakos1, Pedro Machado2, Lars Bauer3, Bengt Hoepken3, Mindy Kim4, Thomas Kumke3, Rachel Tham5 and Martin Rudwaleit6, 1Rheumazentrum Ruhrgebiet Herne, Herne, Germany, 2University College London, London, United Kingdom, 3UCB Pharma, Monheim am Rhein, Germany, 4UCB Pharma, Smyrna, GA, 5UCB Pharma, Slough, UK, Overland Park, KS, 6University of Bielefeld, Klinikum Bielefeld, Bielefeld; Germany Klinikum Bielefeld and Charité Berlin, Germany, and Gent University, Gent, Belgium

    Background/Purpose: The Assessment of SpondyloArthritis international Society (ASAS) recently proposed preliminary, more stringent, data-driven definitions for active and structural MRI lesions of the sacroiliac joint…
  • Abstract Number: 1156 • ACR Convergence 2022

    Serum Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) Is Increased in Patients with Active Ankylosing Spondylitis (AS) and Persists Despite Anti-TNF Treatment

    Charalampos Papagoras1, Styliani Tsiami2, Akrivi Chrysanthopoulou1, Ioannis Mitroulis1 and Xenofon Baraliakos3, 1First Department of Internal Medicine and Laboratory of Molecular Hematology, University Hospital of Alexandroupolis, Democritus University of Thrace, Alexandroupolis, Greece, 2Rheumazentrum Ruhrgebiet, Herne, Ruhr-University Bochum, Herne, Germany, 3Rheumazentrum Ruhrgebiet Herne, Herne, Germany

    Background/Purpose: There is increasing evidence of the pathogenetic role of monocytes and neutrophils in AS, while the neutrophil-to-lymphocyte ratio correlates with disease activity (1). Granulocyte-Monocyte…
  • Abstract Number: 1492 • ACR Convergence 2022

    Treatment with Non-steroidal Anti-inflammatory Drugs Is Associated with Retardation of Radiographic Spinal Progression in Patients with Axial Spondyloarthritis: 10-year Results from the GErman SPondyloarthritis Inception Cohort

    Murat Torgutalp1, valeria Rios-Rodriguez2, Ani Dilbaryan3, Fabian Proft4, Mikhail Protopopov5, Maryna Verba6, Judith Rademacher5, Hildrun Haibel1, Joachim Sieper1, Martin Rudwaleit7 and Denis Poddubnyy4, 1Charité - Universitätsmedizin, Berlin, Berlin, Germany, 2Charité-Universitätsmedizin Berlin, Berlin, Germany, 3Department of Internal Medicine, Moscow City Clinical Hospital, Moscow, Russia, 4Department of Gastroenterology, Infectious Diseases and Rheumatology, Charité – Universitätsmedizin Berlin, Berlin, Germany, 5Charité Universitätsmedizin Berlin, Berlin, Germany, 6Charité-Universitätsmedizin Berlin, corporate member of Freie-Universitat Berlin and Humboldt-Universitat zu Berlin, Department of Gastroenterology, Infectious Diseases and Rheumatology (including Nutrition Medicine), Berlin, Germany, 7University of Bielefeld, Klinikum Bielefeld, Bielefeld; Germany Klinikum Bielefeld and Charité Berlin, Germany, and Gent University, Gent, Belgium

    Background/Purpose: There are conflicting data regarding the effect of nonsteroidal anti-inflammatory drugs (NSAID) on radiographic spinal progression in axial spondyloarthritis (axSpA). The analysis of the…
  • Abstract Number: 1771 • ACR Convergence 2022

    The Effectiveness of a Treat-to-target Strategy in Rheumatic Diseases: A Systematic Literature Review and Meta-analysis

    Yanjie Hao1, Shereen Oon2 and Mandana Nikpour3, 1The University of Melbourne, Melbourne, Australia, 2The University of Melbourne Department of Medicine at St. Vincent’s Hospital Melbourne, Melbourne, Australia, 3The University of Melbourne at St. Vincent's Hospital Melbourne, Melbourne, Australia

    Background/Purpose: The concept of treat-to-target (T2T), a strategy in which treatment is directed to reach and maintain a defined goal such as remission or low…
  • « Previous Page
  • 1
  • …
  • 21
  • 22
  • 23
  • 24
  • 25
  • …
  • 41
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology